News and Media

Press Releases

AVROBIO, Inc. Expands Rare Disease Pipeline with Gene Therapy to Treat Cystinosis

Cystinosis Program Becomes Company’s Fourth Gene Therapy for Lysosomal Storage Disorders Cambridge, MA, October 4, 2017 – AVROBIO, Inc., a clinical-stage biotechnology company developing transformative, life-changing gene

Read More »

AVROBIO, Inc. Expands Rare Disease Pipeline with Gene Therapy to Treat Pompe Disease

Pre-Clinical Program Becomes Company’s Third GeneTherapy for Lysosomal Storage Disorders Pre-Clinical Proof-of-Concept Demonstrated Cambridge, MA, September 20, 2017 – AVROBIO, Inc., a clinical-stage biotechnology company developing transformative, life-changing

Read More »

AVROBIO, Inc. Expands Rare Disease Pipeline with Gene Therapy to Treat Gaucher Disease

Preclinical Proof-of-Concept Achieved, IND-Enabling Activities Underway Cambridge, MA, March 22, 2017 – AVROBIO, Inc., a clinical-stage biotechnology company developing transformative, life-changing gene therapies for rare diseases, today announced the

Read More »

AVROBIO, Inc. Expands Senior Management Team with Three Key Hires

Industry Veterans Bring Deep Industry Experience to Support Future Growth Cambridge, MA, November 9, 2016 – AVROBIO, Inc., a clinical-stage biotechnology company developing transformative, life-changing gene therapies for

Read More »

AVROBIO, Inc. Announces $25 Million Series A Financing to Advance Novel, Clinical-Stage Gene Therapies for Rare Diseases & Cancer

Company Leverages Disruptive Therapies to Create New Paradigms in the Treatment of Fabry Disease and Acute Myeloid Leukemia Cambridge, MA, August 2, 2016 – AVROBIO, Inc, a clinical-stage

Read More »

AVROBIO Awarded Johnson & Johnson Coveted J-Labs Incubator Space

Cambridge, MA May 13, 2016 – AVROBIO, a clinical-stage biotechnology company developing transformative, life-changing gene therapies targeting rare diseases and cancer, today announced it has been awarded

Read More »

SIGN UP for our Press Releases

To receive our press releases, please click on the link to sign up. Thank you!